This trial is evaluating whether Internet-Based Intervention will improve 1 primary outcome and 1 secondary outcome in patients with Head Neoplasms. Measurement will happen over the course of Baseline up to 6 months post-radiation.
This trial requires 300 total participants across 2 different treatment groups
This trial involves 2 different treatments. Internet-Based Intervention is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The most common sign of head tumors is a headache. Other common neurological signs include hearing disturbances (hearing loss), facial palsy, balance disturbances, and tinnitus. All of these symptoms are indicative of tumors localized outside the pituitary gland. If tinnitus is the only symptom, the tumor is unlikely to be inside the pituitary gland. Tumors in the meninges can manifest as meningism. However, their diagnosis and treatment can be complicated by the fact that lesions of these structures may be asymptomatic on a radiographic screening.
Head neoplasms are commonly grouped together by the most likely origin (in the same site as the neoplasm). Head neoplasms are usually of endocrine or connective tissue origin. They have been associated with many different tumor mechanisms. They may present as a neoplasm or as a benign growth.
Given the lack of a standard definition of how head neoplasms are graded, it is difficult to determine the exact number of head neoplasms in this article. The reported head neoplastic incidence rates of 3.4/100,000, which is high compared to most European countries, are in the range of rates recommended by the National Comprehensive Cancer Network. On the basis of the calculated yearly number of new cases, it may be calculated that the average rate for all head cancers in the Netherlands will increase from 0.5 to 6 cases/100,000 per year. From the population based data it may be estimated that about 500,000 cases of primary head and neck cancer will occur in the Netherlands within the next 25 years.
There should be no doubt that a malignant brain tumor cannot be cured. This is particularly the case with tumors that are highly malignant. However, this study showed that it is possible to cure tumors of one, two, or even three other organs (brain, lung, and bladder). The prognosis and the life quality of the patient are more adversely affected if the brain cancer also includes the other organs.
There is not a single treatment that can correct brain tumours; the most important treatment is symptomatic treatment and addressing the associated comorbidities. There is a paucity of randomized controlled trials and evidence from this survey suggests that some treatments with anecdotal evidence may be effective or can improve the tolerability of a patient. Patients should be monitored for improvement once the neoplasm is treated in order to identify the most appropriate neurooncologist to manage their tumors. In patients that are symptomatic, they need to be monitored for any worsening symptoms.
Head neoplasms in some respects present as much of a danger to the well-being of the patient as they do to the physician and patient as a whole. More work is needed to determine appropriate, reliable, and effective diagnostic techniques.
Tumours of the trigeminal ganglion are fast-growing, often aggressive and cause severe disability. We recommend MRI to determine the precise pattern of tumor's spread before deciding on a treatment response.
Data from a recent study supports the findings of a previous study indicating that there are no measurable long-term risks associated with a Internet-based intervention.
There has been no research showing whether an additional internet-based intervention over a conventional cancer information strategy has significant impact on patient outcomes compared with usual care. However, the evidence from this study suggests that the use of internet-based resources in conjunction with conventional information strategies may be effective in encouraging the use of information available both publicly and privately. This is an important finding because of the growing trend towards the publicization of health information via the internet using a combination of approaches such as (i) passive communication through web pages, email and text messaging, (ii) automated contact letters, (iii) electronic media news stories, advertisements and advertisements with a voiceover which may not necessarily have the patient's consent.
It appeared necessary to perform multistage analysis by applying the methodology of multiple-contrast log-likelihood test for linkage. This facilitated the localization of the gene locus to chromosome 12, where the first four nonsynonymous mutations for the development of the familial predisposition to head neoplasms were identified. The presence, in the first kindred, of the same nonsynonymous mutations in members of 3 independent families with familial encephalopathy and an autosomal recessiveness in the same area of a chromosome suggests the existence of a gene or genes underlying familial head neoplasms predisposition which may be a candidate gene for encephalopathy.
Based on the age of presentation, the probability of neuroectodermal tumor is more than twice as high as that of other head and neck tumors. Other risk factors that may contribute are smoking, exposure to ionizing radiation, familial cancer syndromes (e.g. Li-Fraumeni syndrome) and head and neck radiation prophylaxis.